Theracos, Inc.

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Theracos Sub, LLC

Shanghai Zelgen Pharma.tech Co., Ltd.

Suzhou Zelgen Biopharmaceutical Co., Ltd.

Binhua Lv

Brian Seed

Jacques Y Roberge

Ge Xu

Baihua Xu

Yan Feng

Yuanwei Chen

Jiyan Du

Michael J Hadd

Yuelin Wu

Huawei Cheng

Chengwei Li

Congna Wang

Qian Liu

Yanli Song

Shengbin Li

Zelin Sheng

Mengzhuang Cai

Lili Zhang

Jiajia Dong

Benwen Cao

Min Xu

Kun Peng

Xudong Pang

Tao Han

Dawei Cui

Xinxing Tang

Dan Xiao

Peizhong Ni

Runqing Wang

Lianjun Liu

Vasanthakumar Rajappan

Binhua Xu

Chao Guo

Ruifeng Liu

Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and the use thereof are described. Compounds of the present invention have a structure represented by formula (I). Further disclosed are preparation methods for said compounds, and the use of said compounds as KRASinhibitors. The compounds have an excellent ability to selectively inhibit KRAS, improved pharmacodynamic and pharmacokinetic performance, and reduced toxic side effects. 

Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof

Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

Crystalline form of benzylbenzene SGLT2 inhibitor

Deuterated diaminopyrimidine compounds, and intermediates thereof are described. In particular, disclosed are deuterated diaminopyrimidine compounds of formula (I), and pharmaceutical compositions containing such compounds or crystal forms, pharmaceutically acceptable salt, hydrates or solvates thereof. The disclosed deuterated diaminopyrimidine compounds can be used for treating and/or preventing protein kinase-associated diseases, such as cell proliferative disease, cancer, immune disease and the like. 

Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds

Disclosed are deuterated chenodeoxycholic acid derivatives and pharmaceutical compositions containing the deuterated chenodeoxycholic acid derivatives. In particular, disclosed is a deuterated chenodeoxycholic acid derivative of formula (I), or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the same. The deuterated chenodeoxycholic acid derivatives of formula (I) can be used to treat and/or prevent diseases related to the farnesoid X receptor (FXR) and/or G-protein coupled bile acid receptor, such as nonalcoholic steatohepatitis, nonalcoholic fatty liver diseases, gallstones, primary biliary cirrhosis, and cirrhosis.

Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof

Deuterated quinazolinone compounds and pharmaceutical compositions containing such compounds are provided. In particular, deuterated quinazolinone compounds of formula (I) are provided, as well as pharmaceutical compositions containing such compounds or crystal form, pharmaceutically acceptable salts, hydrates or solvates thereof. The deuterated quinazolinone compounds of formula (I) can be used for treating and/or preventing PI3K kinase-associated diseases, such as cancer, cell proliferative diseases and the like. 

Deuterated quinazolinone compound and pharmaceutical composition comprising same

The present invention relates to a phenyl amino pyrimidine compound or a polymorph of a salt thereof, specifically, to N-(cyanomethyl)-4-(2-((4-(2',2&#x2032;,6&#x2032;,6&#x2032;-d-morpholino)phenyl)amino)pyrimidin-4-yl)benzamide, or a pharmaceutically acceptable salt thereof, or a polymorph of a solvate thereof, that is, a compound shown in formula I or salt thereof, or a polymorph of a solvate thereof. The polymorph is suitable for preparing a pharmaceutical composition for suppressing non-receptor tyrosine kinases (such as JAK kinase).

Phenyl amino pyrimidine compound or polymorph of salt thereof

Deuterated diaminopyrimidine compounds and pharmaceutical compositions containing such compounds are described. In particular, disclosed are deuterated diaminopyrimidine compounds of formula (I), and pharmaceutical compositions containing such compounds or crystal forms, pharmaceutically acceptable salt, hydrates or solvates thereof. The disclosed deuterated diaminopyrimidine compounds can be used for treating and/or preventing protein kinase-associated diseases, such as cell proliferative disease, cancer, immune disease and the like. 

Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.

Process for the preparation of benzylbenzene SGLT2 inhibitors

The present invention relates to a deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing the same. Specifically provided are a deuterated phenyl amino pyrimidine compound as represented by formula (I), and pharmaceutical composition containing the compound, or polymorph, pharmaceutically acceptable salt, hydrate or solvate thereof. The compound of the present invention can treat and/or prevent JAK kinase-related diseases, such as bone marrow proliferative disease, cancer, immunologic diseases and the like.

Deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing the same

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.

Deuterated benzylbenzene derivatives and methods of use

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.

Benzylbenzene derivatives and methods of use

Growing community of inventors

Shanghai, China

Binhua Lv